In a significant step forward for lung cancer treatment, the US Food and Drug Administration (FDA) has expanded its approval of Bristol Myers Squibb’s Opdivo (nivolumab). The latest approval allows the immunotherapy to be used in adult patients with resectable non-small cell lung cancer (NSCLC) in combination with platinum-doublet chemotherapy as part of a perioperative […]
The U.S. Food and Drug Administration (FDA) has approved the combination of RYBREVANT (amivantamab-vmjw) and LAZCLUZE (lazertinib) as a first-line therapy for adults with advanced non-small cell lung cancer (NSCLC) characterized by epidermal growth factor receptor (EGFR) mutations. This approval marks a significant advancement in the treatment landscape for patients with EGFR-mutated NSCLC, providing a […]
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at evaluating the efficacy of tiragolumab plus Tecentriq (atezolizumab) and chemotherapy in treating non-squamous non-small cell lung cancer. The study did not meet its primary endpoints of progression-free survival (PFS) and overall survival (OS), signaling a setback in […]
A study has highlighted a significant health concern for men who consume high doses of vitamin B supplements, particularly vitamins B6 and B12. According to research reported by the Daily Mail and conducted by American scientists, these supplements, often marketed for their energy-boosting properties, may substantially increase the risk of lung cancer, especially among smokers. […]
Dizal, a prominent biopharmaceutical company listed on the Shanghai Stock Exchange (SSE:688192), has announced significant clinical results from its WU-KONG1 Part B (WU-KONG1B) study of sunvozertinib, showcasing substantial efficacy in treating non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (exon20ins). The findings were presented at the 2024 American Society of Clinical Oncology […]
At the 60th Annual Meeting of The Society of Thoracic Surgeons (#STS2024), Vergent Bioscience, a Minneapolis-based clinical-stage biotechnology company, presented compelling new data about VGT-309, its investigational tumor-targeted fluorescent imaging agent. This revolutionary agent is designed to visualize primary and metastatic tumor tissue in the lung during surgery, potentially transforming the way lung cancer is […]
Mirati Therapeutics, Inc. (NASDAQ: MRTX), an innovative biotechnology company, has received conditional authorization from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its KRAZATI (adagrasib) monotherapy. This approval marks a pivotal milestone for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who present the KRASG12C mutation and have not […]
Eli Lilly (Lilly) has disclosed the results from two pivotal Phase 3 studies, LIBRETTO-431 and LIBRETTO-531, evaluating the efficacy of Retevmo in treating patients with specific types of advanced or metastatic cancers. These revelations were spotlighted during the ESMO Congress 2023 and simultaneously found a place in the esteemed New England Journal of Medicine. Key […]
The European Union (EU) has given its nod to ENHERTU (trastuzumab deruxtecan) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) that have an activating HER2 (ERBB2) mutation, following platinum-based chemotherapy treatment with or without immunotherapy. This significant decision is backed by the positive outcomes of the DESTINY-Lung02 phase 2 trial, […]
Bristol Myers Squibb (NYSE: BMY) is set to acquire Mirati Therapeutics, Inc. (NASDAQ: MRTX) at $58.00 per share in a cash deal valued at $4.8 billion. Additionally, Mirati Therapeutics stockholders will benefit from a non-tradeable Contingent Value Right (CVR) for each share held, offering a potential $12.00 per share, signaling an extra $1 billion in […]